To estimate the prevalence of congenital CMV infection in Vietnamese neonates and relating morbidity within 2-year follow-up. Along with evaluating the predictive value of the presence and the level of CMV replication in the first trimester in a highly seropositive population
Congenital cytomegalovirus infection (cCMV) is the main non-genetic cause of sensorineural hearing loss (SNHL), and a major cause of neuro-disability. High maternal CMV prevalence seems to be consistently associated with high prevalence of cCMV infection but the associated morbidity might be different from one population to another. There exists no serologic marker useful to differentiate non-primary infection from primary infection. Since the morbidity of cCMV is similar between both primary and non-primary maternal infection, and to be infected in the first trimester is the major risk factor for long-term sequelae in neonates. Hence, it is needed to focus on finding markers that predict cCMV after maternal infection in the first trimester of pregnancy. To date, the epidemiology of cCMV, the morbidity related to cCMV in Vietnamese population and the predictive value of Cytomegalovirus Polymerase Chain Reaction (CMV PCR) in maternal blood and urine in the first trimester remain unknown. Therefore, it is necessary to conduct this study.
Study Type
OBSERVATIONAL
Enrollment
5,000
Hanoi Obstetrics and Gynecology Hospital
Hanoi, Vietnam
RECRUITINGProportion of congenital CMV infection in Vietnamese neonates
Number of CMV positive neonates among all tested neonates
Time frame: Within 7 days from birth
To estimate the prevalence of symptomatic cCMV in neonates
Proportion of neonates presenting with at least one symptom related to cCMV in all cCMV neonates
Time frame: Up to 25 months from recruitment
To estimate the prevalence of cCMV related hearing loss in neonates
Proportion of cCMV related hearing loss in neonates in all cCMV neonates
Time frame: Up to 25 months from recruitment
To estimate the prevalence of cCMV related neurological sequelae in neonates
Proportion of cCMV related neurological sequelae in neonates in all cCMV neonates
Time frame: Up to 25 months from recruitment
To estimate CMV seroprevalence in pregnant Vietnamese women
Proportion of seropositive women in all tested pregnant women, including mother of CMV positive neonates and control group
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal whole blood in the first trimester to predict infection in the neonates
Comparison of the proportion of a positive CMV PCR in maternal whole blood in the first trimester between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal urine in the first trimester to predict infection in the neonates
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Comparison of the proportion of a positive CMV PCR in maternal urine in the first trimester between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal saliva in the first trimester to predict cCMV infection in the neonates
Comparison of the proportion of a positive CMV PCR in maternal saliva in the first trimester between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal whole blood at delivery to predict infection in the neonates
Comparison of the proportion of a positive CMV PCR in maternal whole blood at delivery between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal urine at delivery to predict infection in the neonates
Comparison of the proportion of a positive CMV PCR in maternal urine at delivery between women who gave birth to an infected neonate and women gave birth to an uninfected neonate from control group
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in whole blood in the first trimester to predict the presence of symptomatic cCMV infection in neonates
Comparison of the proportion of a positive CMV PCR in maternal whole blood in the first trimester between symptomatic infected neonates and asymptomatic infected neonates
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal urine in the first trimester to predict a cCMV symptomatic infection in neonates
Comparison of the proportion of a positive CMV PCR in maternal urine in the first trimester between symptomatic infected neonates and asymptomatic infected neonates
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal saliva in the first trimester to predict the presence of symptomatic cCMV infection in neonates
Comparison of the proportion of a positive CMV PCR in maternal saliva in the first trimester between symptomatic infected neonates and asymptomatic infected neonates
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal whole blood at delivery to predict the presence of symptomatic cCMV infection in neonates
Comparison of the proportion of a positive CMV PCR in maternal whole blood at delivery between symptomatic infected neonates and asymptomatic infected neonates
Time frame: Up to 25 months from recruitment
To evaluate the value of a positive CMV PCR in maternal urine at delivery to predict a cCMV symptomatic infection in neonates
Comparison of the proportion of a positive CMV PCR in maternal urine at delivery between symptomatic infected neonates and asymptomatic infected neonates
Time frame: Up to 25 months from recruitment
To evaluate the association between CMV PCR viral load in maternal whole blood at first trimester and at delivery in mothers with infected neonates
Evaluation the change of CMV PCR viral load in maternal whole blood at first trimester and at delivery in mothers with infected neonates
Time frame: Up to 25 months from recruitment
To evaluate the association between CMV PCR viral load in maternal urine at first trimester and at delivery in mothers with infected neonates
Evaluation the change of CMV PCR viral load in maternal urine at first trimester and at delivery in mothers with infected neonates
Time frame: Up to 25 months from recruitment
To evaluate the association between CMV PCR viral load in maternal whole blood at first trimester and at delivery in mothers with uninfected neonates in control group
Evaluation the change of CMV PCR viral load in maternal whole blood at first trimester and at delivery in mothers with uninfected neonates in control group
Time frame: Up to 25 months from recruitment
To evaluate the association between CMV PCR viral load in maternal urine at first trimester and at delivery in mothers with uninfected neonates in control group
Evaluation the change of CMV PCR viral load in maternal urine at first trimester and at delivery in mothers with uninfected neonates in control group
Time frame: Up to 25 months from recruitment
To calculate the false positive rate of CMV PCR on neonatal saliva versus on dry blood spot in screening congenital CMV infection
Calculation of the rate of positive CMV PCR on neonatal saliva with a negative result on CMV PCR on neonatal dry blood spot in all CMV positive on neonatal saliva
Time frame: Up to 25 months from recruitment
To calculate the false positive rate of CMV PCR on neonatal saliva versus on urine in screening congenital CMV infection
Calculation of the rate of positive CMV PCR on neonatal saliva with a negative result on CMV PCR on neonatal urine in all CMV positive on neonatal saliva
Time frame: Up to 25 months from recruitment
To evaluate risks factors for cCMV in Vietnamese women
Factors that may differ between mothers of uninfected neonates and mothers of infected ones regarding maternal age, parity, gestity, twin pregnancy, known health conditions including hypertension, diabetes, HIV, auto immune diseases and living conditions will be analyzed
Time frame: Up to 25 months from recruitment
To estimate the prevalence of symptomatic cCMV at 2 years of age
Proportion of infants presenting with at least one symptom related to cCMV at 2 years of age in all cCMV infants
Time frame: Up to 48 months from recruitment
To estimate the prevalence of cCMV related hearing loss at 2 years of age
Proportion of infants with cCMV related hearing loss at 2 years of age in all cCMV infants
Time frame: Up to 48 months from recruitment
To estimate the prevalence of cCMV related neurological sequelae at 2 years of age
Proportion of infants with cCMV related neurological sequelae at 2 years of age in all cCMV infants
Time frame: Up to 48 months from recruitment
To evaluate the value of a positive CMV PCR in maternal whole blood in the first trimester to predict the cCMV long-term sequelae at the age of 2 years
Comparison of the proportion of a positive CMV PCR in maternal whole blood in the first trimester between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
Time frame: Up to 48 months from recruitment
To evaluate the value of a positive CMV PCR in maternal urine in the first trimester to predict the cCMV long-term sequelae at the age of 2 years
Comparison of the proportion of a positive CMV PCR in maternal urine in the first trimester between between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
Time frame: Up to 48 months from recruitment
To evaluate the value of a positive CMV PCR in maternal saliva in the first trimester to predict the cCMV long-term sequelae at the age of 2 years
Comparison of the proportion of a positive CMV PCR in maternal saliva in the first trimester between between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
Time frame: Up to 48 months from recruitment
To evaluate the value of a positive CMV PCR in maternal whole blood at delivery to predict the cCMV long-term sequelae at the age of 2 years
Comparison of the proportion of a positive CMV PCR in maternal whole blood at delivery between between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
Time frame: Up to 48 months from recruitment
To evaluate the value of a positive CMV PCR in maternal urine at delivery to predict the cCMV long-term sequelae at the age of 2 years
Comparison of the proportion of a positive CMV PCR in maternal urine at delivery between between infected infants with long-term sequelae at 2 years of age and infected infants without long-term sequelae at 2 years of age
Time frame: Up to 48 months from recruitment